AbCellera Results Presentation Deck

FINANCIALS Q2 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 14 Four molecules in the clinic, over a dozen in preclinical development. MOLECULE bamlanivimab (LY-CoV555) bebetelovimab (LY-CoV1404) NBL-012 NBL-015 STAGE Marketed, Emergency Use Authorization (EUA) Phase II Phase I IND approved PARTNER Lilly Lilly NovaRock BOTHERAPEUTICS NovaRock BOTHERAPEUTICS THERAPEUTIC AREA ● COVID-19 COVID-19 dermatology • gastrointestinal disease immunology oncology PROGRAM TYPE AbCellera Discovery Partnership Trianni License

View entire presentation